PharmEasy Secures Rs 1,700 Crore Debt Funding amid Financial Challenges

Mumbai-based healthtech unicorn PharmEasy has successfully raised Rs 1,700 crore ($193 million) in debt funding, spearheaded by 360 One, with contributions from Alkram Ventures, MVS Ventures, Bennett Coleman, and additional investors. This debt round represents the firm’s third financial injection in four years, emphasising its reliance on expensive borrowing to sustain previous loans.

The newly acquired debt aims to facilitate the repayment of its loan from Goldman Sachs, secured in May 2022 for Rs 2,700 crore, which came with a high interest rate to refinance the Rs 2,200 crore loan from Kotak Mahindra Bank, used for acquiring Thyrocare in 2021. Notably, the loan from Goldman Sachs included specific financial stipulations regarding the company’s expenditure, which were not adhered to by June 2023. However, PharmEasy has consistently made all payments punctually.

Details of the Debt Round

The debt round led by 360 One comprises the issuance of 1,700 non-convertible debentures valued at Rs 10 lakh each, according to documents filed with the Registrar of Companies. 360 One’s investment amounted to Rs 1,231 crore, while Micro Labs Limited contributed Rs 210 crore. MVS Ventures infused Rs 78 crore, with Bennett Coleman and Alkram Ventures providing Rs 50 crore and Rs 42 crore, respectively. Other investors, including Kyrush Investments, Medley Pharmaceuticals, and Mahalaxmi Trust, made up the remainder of the funding.

Background and Financial Trends

This funding follows a capital raise of $216 million in April 2024, which reflected a significant 90% drop in valuation to $710 million from PharmEasy’s peak of $5.6 billion in 2021. The round, led by MEMG and supported by Prosus, Temasek, and others, aimed to strengthen financial stability in light of decelerating growth and substantial debt responsibilities. Inquiries directed to PharmEasy did not receive an immediate response.

Founded in 2019, PharmEasy provides pharmaceutical products, diagnostic services, and teleconsultations via its web and mobile platforms. The company has now completed its third round of debt financing, underscoring the ongoing struggle to marry ambitious growth plans with expensive debt dynamics. Over the past two years, the company has experienced the exit of all co-founders alongside major leadership changes, with Rahul Guha, the MD and CEO of Thyrocare, stepping in as MD and CEO of PharmEasy.

Recent Financial Performance

In FY25, PharmEasy reported stagnant revenue of Rs 5,872 crore, while accomplishing a 38% reduction in losses, down to Rs 1,572 crore from Rs 2,533 crore in FY24. This shift indicates slight operational enhancements even while debt obligations continue to be a crucial area of focus.